

Theranostics is what makes care personal.



DISCOVERY	DIAGNOSIS	TREATMENT
<p>TRACERcenter™ Targeted tracer production for prostate imaging using cyclotron-produced $^{68}\text{Ga}^1$</p> <p>Prostate cancer</p> <ul style="list-style-type: none"> • 2nd most common cancer in men worldwide² • 3rd most common overall, 1.4 million new cases in 2020² 	<p>Digital PET/CT and Digital PET/MR with high sensitivity, Q.Clear and MotionFree to personalize dose and image $^{68}\text{Ga}^1$ for diagnosis, staging, or restaging</p> <p>Imaging prostate cancer ^{68}Ga-PSMA¹ PET/CT</p>	<p>Digital SPECT/CT with CZT to quantitatively image $^{177}\text{Lu}^2$ with the right balance of speed, energy, and spatial resolution</p> <p>Flexible AI-enabled applications to help make personalized care decisions and response assessments that are at the heart of theranostics</p>
<p>Imaging the therapy ^{177}Lu-PSMA¹ CZT-SPECT/CT</p>	<p>Radionuclide treatment planning and monitoring</p>	

Integrating products and solutions across care pathways, fueled by AI

DECISION MAKING	THERAPY PLANNING	MONITORING
<p>FROM Too much data, in too many different places</p> <p>TO Integrated, longitudinal insights fueled by AI</p>	<p>FROM Costly R&D</p> <p>TO Precisely targeted clinical trial</p>	<p>FROM Patients only monitored when sick</p> <p>TO Proactive approach to wellness beyond hospital</p>
<p>In-Vivo + In-Vitro</p>	<p>Therapy Delivery</p>	
<p>FROM Protocol driven</p> <p>TO Highly personalized</p>	<p>FROM Complex and lacking precision</p> <p>TO Simplified precision interventions and real-time guidance for better outcomes</p>	

1. Radiopharmaceuticals may not be approved by ministers of health in all regions; ^{177}Lu -PSMA is not an FDA approved therapeutic/tracer

2 Source: Global Cancer Statistics 2020: <https://doi.org/10.3322/caac.21660>